Abstract: HPLC and gas chromatography-mass spectrometry analyses of 18 amino acids, N-acetylaspartate, N-acetylaspartylglutamate, and 5-hydroxyindoleacetic acid, derived from serotonin, and homovanillic acid, derived from dopamine, were performed in CSF collected from a group of patients with schizophrenia who either had been drug free for at least 1 year (n = 5) or were drug naive for psychotropic drugs (n = 21) and in 15 control subjects . Significant differences were found only for taurine (15% lower in the patients) and isoleucine (7% higher) . A number of unidentified substances were detected, one of which proved to be markedly reduced (16%) among the schizophrenic patients . Liquid chromatography-mass spectrometry with continuous flow-fast atom bombardment interface allowed us to identify this substance as y-glutamylglutamine . The decreased level of y-glutamylglutamine may reflect a deficiency in the yglutamyltransferase system, a system probably involved in glutamate uptake, or a deficiency in glutamine, an important precursor of releasable glutamate. Although glutamate was nonsignificantly reduced in the patients, it was one of the five substances (including -/-glutamylglutamine) that were necessary for the best discrimination between the schizophrenic patients and the controls . These findings support the notion that the glutamatergic system is affected in schizophrenic disorders . In addition, they underscore the need to apply rigid bioanalytical techniques and use drug-naive patients to gain in-depth information on the pathophysiology of brain disorders such as schizophrenia. Key Words: Amino acids-NAcetylaspartate-N-Acetylaspartylglutamate-5-Hydroxyindoleacetic acid-Homovanillic acid-Cerebrospinal fluid-Schizophrenia .
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Schizophrenia is a nosological concept comprising a large variety of signs and symptoms that make a unifactorial explanation of causality unlikely . In psychiatric research, two major theories on the pathophysiology of this disorder have been developed during the past decades . One assumes a dysfunction of the 2652 monoaminergic and, in particular, the dopaminergic systems ; whereas the other claims a role for the excitatory amino acids, especially glutamate.
Based on the psychotomimetic properties of amphetamine, which is a dopamine agonist, and observations that almost all antipsychotic medications counteract dopamine activity in the brain, Matthysse ( 1973) proposed that schizophrenic illness is a manifestation of a hyperdopaminergic state. But this initial view was not unequivocally supported by subsequent studies, because conflicting observations were reported regarding homovanillic acid (HVA) concentrations in CSF, plasma, and postmortem brain tissue of individuals with schizophrenia (for an overview, see Davis et al ., 1991) . During the past few years, however, evidence has been accumulated that schizophrenic disorders may be characterized by both hypodopaminergia in the mesocortical dopamine neurons and hyperdopaminergia in the mesolimbic dopamine neurons (Davis et al., 1991) . D2-like receptors were reported to be elevated in postmortem brain tissue of schizophrenic patients (Seeman et al., 1990) , which supports the hypothesis that dopaminergic neurotransmission in schizophrenia is enhanced through overactive response by D2 receptors . This concept has been criticized because clozapine, which has only low affinity for D2 receptors, is clinically a highly effective neuroleptic . Recently, however, the group led by Seeman demonstrated the existence of a polymorphic D4 receptor to which clozapine binds with an affinity 10 times higher than to any other yet-characterized dopamine receptors (Van Tol et al ., 1992) . It is interesting that the same group found D4 receptors to be elevated in the brain of patients with schizophrenia (Seeman et al ., 1993) .
The second major hypothesis, as originally formulated by Kim and colleagues (1980) , claimed a role for excitatory amino acids, i .e ., glutamate, in the pathophysiology of schizophrenia. On the basis of decreased levels of glutamate in the CSF of individuals with schizophrenia, these authors postulated that either a hyperactivity of dopaminergic neurons leads to an enhanced inhibition of glutamate release or a hypofunction of the glutamate receptor causes the decreased glutamate release. Indeed, in rodents, the release of glutamate from the striatal terminals is inhibited by dopamine (see Carlsson and Carlsson, 1990) . The reformulation of the glutamatergic hypothesis is based on the observation that phencyclidine (PCP) elicits both productive and deficit symptoms of schizophrenia. Although PCP exerts its effects in part via central dopamine systems, it is a potent and noncompetitive antagonist at the N-methyl-D-aspartate (NMDA) receptor that has distinct recognition sites for glutamate, aspartate, and glycine. When PCP binds to its receptor sites within the NMDA ion channels, these voltagedependent channels are blocked. As a result, the flow of ions into the channel is blocked and the effects of' NMDA agonists such as glutamate or glycine are antagonized (see Heresco-Levy et al ., 1993) . Thus, the current hypoglutamatergic theory of schizophrenia proposes diminished glutamatergic neurotransmission at the level of the NMDA-receptor site (Deutsch et al ., 1989 ; Squires and Saederup, 1991) .
Although both the dopaminergic and glutamatergic hypotheses of schizophrenia have stimulated intense work in this field, there has been neither unequivocal support for nor clear rejection of either theory, mainly because in vivo studies in humans are limited to brain imaging studies and bioanalysis of CSF content. Assuming that changes in CSF composition are a direct or indirect reflection of changes in neurotransmitterreceptor action in brain areas involved in the pathology of schizophrenia, we applied a high-powered bioanalytical method [HPLC, gas chromatography (GC)], which enables determination of amino acids, monoamine metabolites, N-acetylaspartate (NAA), and Nacetylaspartylglutamate (NAAG) levels and identification of heretofore unknown compounds. As a study sample, we used a group of patients with schizophrenia in whom long-term changes secondary to previous antipsychotic treatment could be excluded .
MATERIALS AND METHODS

2653
Subjects
Twenty-six inpatients ( 15 women, l l men ; age range, 21-53 years) with a diagnosis of a schizophreniform or a schizophrenic disorder according to the Diagnostic and Statistical Manual (#'Mental Disorders, third edition, revised (DSM-III-R) (American Psychiatric Association, 1987 ; schizophreniform disorder, n = 9 ; schizophrenic disorder, paranoid subtype, n = 13 ; schizophrenic disorder, disorganized subtype, n = 4), participated in the study . The diagnoses were verified by the Structured Clinical Interview for DSM-III-R (SCID; German version : Wittchen et al ., 1990) . None of the participants fulfilled DSM-111-R diagnostic criteria for any other psychiatric disorders. According to the criteria established by the SCID, 15 patients were rated to be moderately ill and the remaining 11 patients severely ill . Four patients had been free of psychoactive medication for at least I year and one patient for 8 years. The remaining 21 patients were drug naive in this regard . Furthermore, none of the patients had received any medication during the 2 months before lumbar puncture .
Fifteen age-and sex-matched subjects (nine women, six men; age range, 19-58 years) who had been admitted to the neurological ward for diagnostic clarification of health problems [headache, hypertension, PRIND (prolonged reversible ischemic neurologic deficit) occasional spasms, low back pain] served as the control group. In these subjects, internal, neurological, and psychiatric disorders were excluded after a thorough examination . None of these subjects had received any medication during the 2 months before lumbar puncture .
The experimental protocol was approved by the Ethics Committee for Human Experiments of the Max Planck Institute of Psychiatry .
CSF sampling procedure After 1 night of bed rest and fasting, subjects were placed in a sitting position at 0800 h. After administration of an intradermal xylocaine anesthesia, an 18-G 32, or a 19-G 3'-, Yale spinal needle was inserted into the lumbar subarachnoid space through the L3-L4 or L4-L5 interspace . After collection of CSF, 5 ml of the fluid was transferred into an icecooled test tube . The CSF was vortex mixed and aliquoted into five 1-ml vials. These vials were then immediately frozen and stored at -80°C until analysis .
Materials
Reference amino acid solutions were prepared with crystalline amino acids dissolved in water at a standard concentration of 0.1 pM and frozen in aliquots at -20°C. AGI-X8 anion exchanger (200-400 mesh, chloride form) was obtained from Bio-Rad (Richmond, CA, U.S .A .) and converted to the formate form . HCl (0 .5 M) in methanol was prepared by bubbling HCl gas through methanol and was stored in ampules at -30°C. N-Acetyl-t-glutamyl-t-glutamate was synthesized from i_-glutamyl-t-glutamate (Bachem; Bubendorf, Switzerland) by treatment with acetic anhydride and was purified by ion-exchange chromatography. All other solvents and chemicals used were of commercial analytical grade from Merck (Darmstadt, Germany) or Fluka (Buchs, Switzerland) .
CSF deproteinization
The samples were thawed slowly on ice. Internal standard (norvaline ; final concentration, 2 pM) was then added and the samples were deproteinated by ultrafiltration at 18,300 g (4°C) in Millipore Ultrafree-MC filter units (10,000 molecular weight cutoff) . This method allowed deproteinization without using sulfosalicylic acid, which, at concentrations > 1 %, has been shown to increase CSF GABA concentrations and lead to falsely high levels of aspartic and glutamic acids (Ferraro et al ., 1983) . Care was also taken to maintain CSF at ice-bath temperature throughout deproteinization and filtering procedures to avoid enzyme-mediated breakdown of bound to free amino acids, as otherwise occurs in the case of GABA (Grossman et al ., 1980) . o-Phthalaldehyde (OPA)-precolumn derivatization and HPLC analysis of CSF The HPLC system consisted of a Hewlett-Packard chromatograph (Model 1090), combined with a variable autoinjector, a cooled (4°C) autosampler, and a programmable fluorescence detector (HP 1046A) . Analytical Hyperchrome HPLC columns, 250 X 4.6 mm (Bischoff, Leonberg, Germany), packed with Hypersil ODS 5 pen (Shandon, Cheshire, U.K .), were used in combination with a guard column .
The samples were analyzed by OPA precolumn derivatization, followed by reversed-phase HPLC (Lindroth and Mopper, 1979 ) . An automated on-line derivatization technique (Klancnik et al ., 1992) was used . A linear gradient elution of 6-100% of mobile phase B [acetonitrile/0.I M sodium acetate (8 :2)] in mobile phase A [0 .03 M sodium acetate (pH 7 .0)/0.5% tetrahydrofuran] was performed for 85 min at a flow rate of 0.5 ml/min . Fluorescent compounds were monitored using an excitation wavelength of 230 nm and an emission wavelength of 455 urn. The detection limit was -10-50 fmol and the relative standard deviation for peak areas based on 10 injections was 1-4% . The quantitation was based on area measurements and the internal standard method .
Determination of monoamine metabolites
In a subsample of 17 patients [nine women, eight men; mean age, 30 .2 -} 8.1 (SD) years; age range, 21-53 years; schizophreniform disorder, n = 6 ; schizophrenic disorder, paranoid subtype, n = 8 ; schizophrenic disorder, disorganized subtype, n = 3] and of nine control subjects (six women, three men; mean age, 31 .4 ± 11 .2 years; age range, 19-47 years), HVA and 5-hydroxyindoleacetic acid (5-HIAA) were determined . After centrifugation, 10 y1 of CSF was analyzed by reversed-phase HPLC (LiChrospher C18, 4 X 120 mm) using isocratic elution with 0.1 M sodium acetate, 0.1 M citric acid, 0.1 mM EDTA, 2.0 mM heptanesulfonate, and 2% methanol in water at a flow rate of 0.8 ml/min . The compounds were monitored using a Gyncothec (Germering, Germany) electrochemical detector operated at 0.77 V . Calculations of concentrations were performed relative to external standards.
Determination of NAA and NAAG
To aliquots of 40 pl deproteinated CSF, 600 pmol Nacetyl-L-glutamyl-L-glutamate was added as the internal standard. In unspiked CSF, this compound was not detectable . NAA, NAAG, and the standard were purified by an ion-exchange procedure and esterified with HCl in methanol, and the derivatives were then extracted and taken up in toluene/ethyl acetate (9 :1, vol/vol) as described by Zollinger et al . (1990) . These samples were analyzed by GC. Injection was performed in the on-column mode . The GC instrumentation consisted of a Model 3700 gas chromato-graph from Varian (Walnut Creek, CA, U.S .A .) with a nitrogen/phosphorus-specific detector. The components were separated on an SE-54 Permabond column (Macherey-Nagel, Düren, Germany) with helium as carrier gas. For calibration, artificial samples containing known amounts of NAA, NAAG, and the internal standard in water were treated and measured the same way as the CSF samples. For both NAA and NAAG, the calibrations were linear in the relevant range and relative standard deviations were estimated to be below ± 15% for the largest values measured in the biological samples and below ±30% for the smallest ones .
Isolation and characterization of P15.5
In addition to aforementioned amino acids, several unidentified substances were observed and quantified in CSF of patients and control subjects by HPLC after OPA derivatization . One of these compounds, named P15.5, showed a significantly lower concentration in CSF of the patients than in that of the controls (see Results) . Several different methods were used to identify P15 .5 chemically .
The elution time of the OPA derivative of P15.5 (OPA-P15.5) was compared with that of OPA derivatives of various commercially available polar compounds [cysteic acid, cysteine sulfinic acid, homocysteic acid (HCA), homocysteine sulfinic acid (HCSA), ,(3-aspartylglycine, 6-aspartylalanine, y-glutamylglutamate, y-glutamylglutamine (y-GluGln), y-glutamylglycine, y-glutamylalanine, and y-glutamyltaurine] . Usually, 10 pl of CSF was spiked with 2 pmol of reference compound in 2 pl of water. Three different pH values (6 .0, 7.0, and 8.0) of the mobile phase A and a less steep gradient than in the standard analysis were used . Among all the substances tested, only the OPA derivative of the dipeptide y-Glu-Gln coeluted with OPA-P15 .5 under all three conditions .
As the OPA derivatives are not stable enough to be isolated for further characterization, CSF was treated with 9-fluorenylmethylchloroformate (FMOC-Cl) to produce stable and fluorescent N-9-fluorenylmethyloxycarbonyl (FMOC) derivatives according to the procedure of Einarsson et al . (1983) . A component ("FMOC-P15 .5") eluting at the retention time of the FMOC derivative of y-Glu-Gln was collected, purified, and investigated subsequently by liquid chromatography-mass spectrometry (LC-MS), as follows: Starting with a total of 2 ml CSF, three consecutive steps of purification by HPLC on different reversed-phase columns and with different mobile phases were performed. The finally collected fraction contained -200 pmol FMOC-P15 .5 (assuming the same response factor as FMOC-y-Glu-Gln) and was subjected to micro-LC coupled to MS .
The LC-MS instrumentation consisted of the following components : a dual syringe gradient system Model 140A (Applied Biosystems ; Foster City, CA, U.S .A .), a precolumn splitting device, an injector, a 150 X 0.32-mm fused-silica column packed with 3 yen Hypersil RP-18 stationary phase (LC Packings ; Amsterdam, The Netherlands) connected in series to a UV detector (Model 785A, Applied Biosystems) and then to a Finnigan MAT (Bremen, Germany) continuous flow-fast atom bombardment (CF-FAB) interface, coupled to an MAT 90 (Finnigan MAT) double-focusing mass spectrometer . Compounds were eluted with a gradient of water against acetonitrile/water (9 :1, vol/vol), both containing 2 vol-% glycerol and 0.15 M acetic acid . The flow rate through the column and onto the FAB target was 3-5 p.1/min . The FAB gun was operated with xenon at -7 kV . The ion source temperature was 50°C . Positive and negative ion spectra were taken at a resolution of -900 .
To show that the compounds termed FMOC-P15 .5 and OPA-P 15 .5 were indeed derivatives of the same substance, 40 pinol of purified FMOC-P15 was treated with 20 pl of triethylamine for I h at 50°C to cleave the FMOC group . The sample was evaporated to dryness, redissolved in 60 pl of water, and analyzed by OPA-precolumn derivatization HPLC as described above . As expected, a peak at the retention time of OPA-P15 .5 resulted .
Statistical methods
In addition to calculation of descriptive statistics (mean ± SD), an analysis of covariance (ANCOVA) was performed, with age and sex as the covariates . When more than two groups were compared, an ANOVA was performed ; in case of significant main group effects, group-by-group comparisons were calculated using Student's t test (method : "modified least significant difference tests" to control for the increased type I error rate) . In addition, linear canonical discriminant analysis (method : minimizing Wilks' lambda ; validation method : "jack knife") was performed to analyze the pattern of the several compounds in the patients and the control subjects . Pearson product-moment correlation coefficients were calculated to assess correlations (level of significance : 5%, two-tailed) .
RESULTS
Analytical aspects
Figure l shows typical HPLC chromatograms of a CSF sample and of reference amino acids . The OPA derivatives of most amino acids [including aspartate (Asp), glutamate (Glu), a-aminoadipic acid (a-AAA), phosphoethanolamine (Pea), asparagine (Asn), serine (Set), citrulline (Cit), glycine (Gly), threonine (Thr), arginine (Arg), alanine (Ala), taurine (Tau), tyrosine (Tyr), methionine (Met), tryptophan (Trp), phenylalanine (Phe), isoleucine (lie), and leucine (Leu) ] were well resolved . However, coelution of Gln with histidine (His), of GABA with homocarnosine, and of HCA with HCSA occurred . Therefore, these compounds were quantified together .
Isolation of P15.5 and its identification as y-Glu-Gln
The chromatographic retention times of OPA-P15 .5
under three different mobile phase conditions suggested strongly that the compound was identical with OPA-y-Glu-Gln, but because of the complexity of the composition of CSF, additional procedures were performed to confirm the structure of P15 .5 . In all of the chromatographic systems used for isolation and purification of FMOC-P15 .5 from the large excess of other derivatized and underivatized endogenous components, this compound eluted at the same retention time as FMOC-y-Glu-Gln . In several systems, coelution of FMOC-P15 .5 with synthetic FMOC-y-Glu-Gln was substantiated by coinjection of the two compounds . The positive and negative ion CF-FAB mass spectra from FMOC-P15 . (Fig . 2) . These spectra were indistinguishable from the corresponding spectra of synthetic FMOC-y-Glu-Gln . The chromatographic and mass spectral data provided solid evidence that the two compounds are identical .
Clinical aspects
After controlling for possible effects of age and sex, the CSF levels of NAA and NAAG as well as of 5-HIAA and HVA were within the same range in the patients and the control subjects (Table 1) . With regard to the amino acids, Ile was significantly higher and Tau was significantly lower in the patients than in the controls . Furthermore, Glu was lower in the patients ; however, this difference did not quite reach the level of significance (p < 0 .10) . The CSF concentrations of the remaining amino acids investigated were similar in the patients and the control subjects . Among the unidentified compounds, P15 .5 (newly identified as the dipeptide y-Glu-Gln) was significantly decreased in the patients . t. Neuro,henr . Vol. 6.5, No. 6, 1995 Age effects Significant age effects were found for Gly only . Calculation of Pearson correlation coefficients showed a positive and significant association of age and Gly in the total sample (r = 0 .39, p < 0 .05) but neither for the patient group (r = 0.35, p > 0.10) nor for the control subjects alone (r = 0.41, p > 0.10) . The correlation coefficients between age and NAA, NAAG, the amino acids, y-Glu-Gln, and the monoamine metabolites were far from being of significance (r < 0.20, p > 0.25) .
Sex effects
ANCOVA revealed significant effects of sex on Asp, Cit, and y-Glu-Gln . Although Asp was, on average, elevated in women compared with men, no significant main group effect was found ( Table 2) . The values of both Cit and y-Glu-Gln showed a significant main group effect, which in the case of Cit was due to elevated concentrations of this compound in the male controls compared with the female controls . Regarding the y-Glu-Gin values, the main group effect was due to significantly diminished values in the female patients compared with the male patients and female control subjects . Although on average the male patients had lower y-Glu-Gln values than the male controls, the difference was not statistically significant.
Severity of illness
To test for influences of severity of illness, we compared moderately ill patients (n = 15), severely ill patients (n = l I), and control subjects (Table 3) . There were significant main group effects for NAA, Tau, Thr, and y-Glu-Gln . NAA was higher and Thr was lower in the severely ill patients than in the moderately ill patients . Furthermore, Thr was lower in the severely ill patients than in the control subjects . Regarding Tau and y-Glu-Gln, the two patient subsamples had similar values, both of which were significantly lower than that of the control group . 
Course of illness
To control for the duration of illness, we divided the patient sample into the following three groups (DSM-III-R definition) : "acute" (schizophreniform), duration < 6 months (n = 9) ; subchronic, between 6 months and 2 years (n = 9) ; and chronic, >2 years (n = 8) . ANOVA yielded significant main group effects for Ile, Tau, and y-Glu-Gln (Table 4) . Compared with the control subjects, y-Glu-Gin was decreased in the acute patients, Ile was increased in the acute and subchronic patients, and Tau was decreased in all three subgroups of patients .
Acute exacerbation of illness
To determine which of the compounds might be altered, dependent on the state of the illness, we compared the patients with an acute exacerbation of the disorder at the time of investigation (n = 20; 11 women, nine men ; mean age, 30.9 --6 .0 years) and those without (n = 6 ; four women, two men, mean age, 36.8 ± 11 .4 years) . The only compound differing significantly between the two subgroups was Asp, which was higher in the patients without an acute exacerbation [326 _-89 and 221 ± 99 pmol/ml ; F(1,24) = 5 .30, p < 0.05 J .
Discriminant analysis
All of the compounds (except HVA and 5-HIAA) were used as discriminating variables, and the grouping variables were control subjects versus schizophrenic patients . The following compounds were necessary for the best discrimination : Tau, y-Glu-Gln, Ile, Glu, and Asp . With the discriminant function obtained, -83% of the subjects were classified correctly (Table  5 ) . The combined use of the five compounds differentiated schizophrenic patients from control subjects with a specificity of 92.3% (percentage of correctly classified schizophrenic patients) and a sensitivity of 66 .7% (percentage of correctly classified control subjects) . All data are mean ± SD values . "p < 0.01 ;''p < 0 .05 ;`p < 0 .001, by ANCOVA .
Schizophrenic patients, n = 17 ; control subjects, n = 9 .
DISCUSSION
In the present study, we investigated NAA, NAAG, amino acids, monoamine metabolites, and a component (P15.5) that was identified as y-Glu-Gln in the CSF of 26 schizophrenic patients who either were drug naive (81%) or had been off psychoactive medication for between 1 and 8 years (19%) . Compared with the control subjects, the patients had significantly higher concentrations of Ile and significantly lower concentrations of Tau and y-Glu-Gin . The concentration of Glu, on average, was lower in the patients (this difference approximated significance) . For the remaining amino acids measured, as well as NAA, NAAG, HVA, and 5-HIAA, the groups did not differ . For the best discrimination between schizophrenic patients and controls, the following compounds were necessary : Glu, y-GluGln, Asp, Tau, and Ile. The discriminant function computed with these compounds classified 83% of the subjects correctly. The specificity was 92% and the sensitivity was 67%. 
Analytical considerations
We took special care to maintain CSF at ice-bath or lower temperature throughout the sampling, deproteinization, and filtering procedures. These precautions prevent enzyme-mediated breakdown of bound to free amino acids, the occurrence of which has been demonstrated in the case of GABA (Grossman et al., 1980) . Moreover, we avoided using acid for deproteinization because it could have led to falsely high levels of Asp and Glu (Ferraro et al., 1983) . Beyond this, we found y-Glu-Gin to be unstable when we used strong acid for deproteinization .
Particular difficulties were encountered in the recognition of y-Glu-Gln at low levels in physiological samples using ion-exchange chromatography, a technique used in dedicated amino acid analysis, because of variations in peak shape and retention time (Hammond et al ., 1990) . With OPA-precolumn derivatization reversed-phase HPLC, depending on the pH of the mobile phase, the risk of coelution of y-Glu-Gin with Glu is high, especially with a steep gradient of the mobile J. Neurochem., Vo/. 65, No. 6, 1995 phase . Coelution probably occurred in the case of some reports where high levels of Gin were observed with this method. At pH 7.0 and with a shallow gradient, the OPA derivative of y-Glu-Gin eluted -1 min after that of Glu ( Fig. 1 ) and its averaged level in control CSF was about five times higher than that of Glu. Although present at a higher level than Glu, y-GluGln has not been measured routinely in CSF, probably due to the aforementioned analytical difficulties . For identification of P15 .5 as y-Glu-Gln, we found it essential to use the LC-MS coupling via the CF-FAB interface to obtain high-quality spectra of the small amounts of compound isolated . Traces of residual salts, which often reduce considerably the sensitivity of FAB-MS, and other remaining contaminants were well separated from the analyte by the on-line micro-HPLC, and spectra taken immediately before and after the elution of the analyte allowed an optimal subtraction of the high background from the FAB matrix in the low mass region of the spectra .
Pathophysiological considerations
We investigated the CSF levels of NAA and NAAG because of the metabolic and physicochemical relationship of these two compounds to the excitatory K. Q. DO ET AL . SP, schizophrenic patients ; CS, control subjects ; W, women; M, men; MLSD, modified least significance difference test ; (-), not tested ; NS, not significant . " p < 0.05; " 1) < 0.01, by ANOVA. ' Significant group differences .
amino acids Asp and Glu . Whereas the functions of NAA are still unclear, NAAG is regarded as a potential neurotransmitter or neuromodulator that acts selectively on the NNIDA-type of ionotropic glutamate receptor (Blakely and Coyle, 1988; Trombley and Westbrook, 1990 ) .
In the schizophrenic patients, the CSF concentration of NAA and NAAG were well comparable with those observed in the control subjects . Similar results recently were reported by Swahn (1990) . Furthermore, no associations were obtained between these compounds and the demographic and clinical characteristics of the subjects (i .e., age, sex, and course of the disorder) . However, the moderately ill patients had significantly lower levels of NAA than the severely ill patients, with that of the control subjects in between . In addition, Nasrallah et al . (1991) , using the in vivo magnetic resonance spectroscopic method, found decreased NAA concentrations in the right (but not in the left) hippocampus of schizophrenic patients. Therefore, one might suggest a possible modulatory involvement of NAA at least in the severity of this disorder. No definite conclusion can be drawn about whether NAAG represents a primary candidate in the pathophysiology of schizophrenia, because in the pres- ent study its CSF level was found to be similar in the patients and the control subjects ; but Tsai et al . (1991) reported preliminary data showing an elevated postmortem tissue level of NAAG in the frontal and parietal cortex of schizophrenic patients . The CSF concentrations of the monoamine metabolites HVA and 5-HIAA were very similar in the schizophrenic patients and the control subjects . Furthermore, no clear associations between these metabolites and age, sex, severity of the illness, or an acute exacerbation of the disorder emerged. In general, these findings are in accordance with those of numerous other CSF studies (see Widerl6v, 1988; Pickar et al ., 1990) . In the meantime, it has become clear that the CSF sampling technique for determination of HVA concentrations bears several limitations ; e .g., there is a substantial gradient along the spinal cord, acute neuroleptic treatment can elevate HVA but this effect may be abolished during chronic neuroleptic administration, and, finally, the degree of motor activity before lumbar puncture affects substantially the CSF HVA concentrations . In the present study, some (but not all) of these limitations were controlled [e .g., motor activity before lumbar puncture, drug status, and possible circadian influences (see Materials and Methods)] ; but nevertheless the results obtained do not fit with the hypothesis that schizophrenia is a manifestation of a hyperdo- Davis et al . (1991) , that schizophrenia may be characterized by both a hyper-and a hypodopaminergic state, our findings do not support the dopamine theory of schizophrenia, because the CSF HVA concentration was not increased or decreased in either the total patient sample or various subgroups of the sample . The analysis of the amino acid concentrations revealed significantly diminished concentrations of Tau and significantly elevated levels of lie in the patients with schizophrenia compared with the controls . Furthermore, in the patients, the dipeptide y-Glu-Gln was diminished highly significantly and the Glu concentration tended to be decreased . The remaining amino acids investigated, including Asp, Gly, Ser, and GABA, did not differ between the two samples . Thus, the changes observed for a few amino acids appear to be selective against the background of a majority of unaffected amino acids .
In the present study, Tau, an inhibitory amino acid that is also involved in osmoregulation (for an overview, see Huxtable, 1992) , was found to be reduced significantly in the CSF of the schizophrenic patients regardless of the patient's age and sex as well as the course and severity of the illness . These observations are at odds with reports in the literature (Korpi et al ., 1987 ; Macciardi et al., 1990 ; Rao et al., 1990; PrietoRinc6n et al., 1991 ) . An adequate explanation of these discrepancies is difficult . One might argue that most of our patients were drug naive, whereas in the other studies the patients were on neuroleptics (Macciardi et al ., 1990) , they were off drugs for 13-45 days (Korpi et al., 1987) , or they were a mixed sample in this regard (Prieto-Rinc6n et al ., 1991 ) . To our knowledge, no study has focused on the effects of neuroleptics on the CSF concentration of Tau . However, at least the serum concentrations of Tau were reported to be similar in drug naive and off-drug and on-drug schizophrenic patients (Rao et al., 1990) , rendering pharmacological influences unlikely . One might further speculate that the differing methods used could J. Neurochern ., Vo/ . 65, No . 6, 1995 Age (yr) Women/men 33 .3 ± 5 .7 7/2 34 .9 ± 9 .5 6/3 28 .0 } 6.6 6/2 36 .0 ± 12 .5 9/6 1 .25 X2 (3) be responsible for the discrepancies between our observation and those reported by others . However, the decrease in Tau observed in the present study is consistent with findings of others that the enzymes methionine adenosyltransferase and serine hydroxymethyltransferase, which are responsible for the synthesis of the Tau precursors S-adenosylmethionine and Ser, have decreased activity in schizophrenia (Carl et al ., 1978 ; Kelsoe et al ., 1982) .
As in the present study, Macciardi et al . (1990) observed elevated Ile levels in the plasma of schizophrenic patients. Furthermore, in the present study Ile was one of five amino acids necessary for the best discrimination between the patients and the controls. However, the significance of these observations remains unclear, not only because other investigators reported quite undisturbed levels of this compound in both drug-naive and drug-free schizophrenics (Rao et al ., 1990 ; Pietro-Rinc6n et al., 1991) , but also because, so far, no solid hypothesis can be formulated about a possible involvement of Ile in the etiology or the pathophysiology of schizophrenia .
In the schizophrenic patients, the mean CSF concentration of Gin was diminished compared with control subjects. Although this difference failed to reach statistical significance (0.05 < p < 0.10), it is sufficiently high (-25%) to warrant a comment here. Several authors did not find any changes in the Glu concentrations in serum, plasma, or CSF of schizophrenic patients (Perry, 1982; Gattaz et al., 1985; Korpi et al., 1987) . On the other hand, the present observation of decreased Glu is in line with that reported by Alfredsson et al . (1985 ) , Rao et al. (1990) , and Prieto-Rinc6n et al . (1991) . Thus, there is some evidence for both the initial "glutamatergic theory" (Kim et al., 1980) and its modification, in which a dysfunction of the PCP/NMDA-receptor complex is postulated as being primarily involved in schizophrenic disorders (Deutsch et al., 1989; Heresco-Levy et al., 1993) . Moreover, the present investigation provides additional evidence supporting rather than refuting the "glutamate theory" ; i.e., Glu was one of the five amino acids necessary to best discriminate between schizophrenic patients and controls, a finding similar to that noted by Macciardi et al. (1990) , and y-Glu-Gln was significantly decreased in the patients, a finding that is also consistent with a general perturbation of Glu metabolism (for discussion, see below) .
The CSF concentration of the dipeptide y-Glu-Gln was diminished highly significantly in the schizophrenic patients compared with the control subjects . This finding was independent of the severity of the disorder and whether the patients were investigated during an acute exacerbation of the disorder. Although a significant sex effect was observed, in that women showed lower values than men, subsequent analyses revealed that this effect was apparently independent of whether the subjects were patients or controls . On the other hand, the level of y-Glu-Gln was most markedly decreased in those patients with a relatively short duration of the disorder (<6 months), indicating a functional role of this dipeptide predominantly during the initial course of schizophrenic disorders .
Up to now, no consideration has been given to a possible involvement of y-Glu-Gln in the pathophysiology of schizophrenia. This dipeptide was first isolated from bovine brain (Kakimoto et al., 1964) and has been reported to be widely distributed in various mammalian tissues and human brain areas (Kanazawa and Sano, 1967 ; Sano, 1970) . It has also been identified in human plasma and CSF (Hammond et al., 1990) . The y-Glu dipeptides are most probably synthetized by the enzyme y-glutamyltransferase, a membrane-bound enzyme that is involved in transport processes across the cell membrane of glutathione, yglutamyl dipeptides, and amino acids in the y-glutamyl cycle (Meister and Anderson, 1983) . Indeed, a significant pathway of glutathione breakdown involves a reaction, catalyzed by y-glutamyltransferase, in which the y-glutamyl moiety is transferred to an amino acid acceptor, with L-Gin and L-Met being the best acceptors (Tate and Meister, 1974) . Furthermore, y-glutamyltransferase has been proposed to be involved in the transport of some amino acids, including Gin and Gin into various brain compartments (Emmuels et al., 1978; Lisy et al., 1983 ; Kvamme et al., 1985) . This is supported by the fact that y-glutamyltransferase is associated with glutamatergic structures in the hippocampus (Stastny et al., 1988) , one of the brain regions thought to be involved primarily in schizophrenia (e .g., Altshuler et al ., 1987) , and that the Glu uptake in brain slices and cell cultures is reduced in the presence of a y-glutamyltransferase inhibitor (Lisy et al ., 1983 ; Jankaskova et al., 1992 ) . Thus, the decreased level of y-Glu-Gln may reflect a deficiency in the y-glutamyltransferase system (either in its level or its activity) or a deficiency in Gin, an important precursor of releasable Gin . In both cases, our finding of diminished yGlu-Gin concentrations is related to Gin and would be consistent with the hypothesis that this excitatory neurotransmitter and possibly the NMDA receptor are involved in the pathophysiology of schizophrenia . In this context, it is worth noting that Met given per os has been shown to be the only amino acid that exacerbates the psychotic symptoms in schizophrenic patients (Park et al., 1965) . This observation might be related to a deficit in the y-glutamyltransferase system in which Met competes with Glu. An excess of Met would impede the already deficient transport of Gin. However, the assumption that a decreased level of yGlu-Gln reflects a deficiency in the T-glutamyltransferase system, which would be in line with the glutamatergic and the PCP/NMDA-receptor hypothesis, remains speculative .
In summary, our findings obtained in patients with schizophrenic disorders who either had been drug free for > 1 year or were drug naive provide little support for the dopaminergic theory of schizophrenia ; i .e., the CSF concentration of the monoamine metabolites investigated did not differ between the patients and the control subjects . However, there were several observations that fit well with the glutamatergic hypothesis of schizophrenia . Although the CSF concentration of Gin showed a tendency to be decreased only in the patients, this excitatory amino acid was one of the five amino acids necessary for the best discrimination between the patients and the controls. Furthermore, the compound that was identified as y-Glu-Gln was diminished highly significantly in the patients. Inasmuch as this dipeptide appears to be involved in transport processes of both Gin and Gin, the latter being the precursor of releasable Glu, this finding provides strong support for the glutamate hypothesis . Moreover, the decreased CSF concentration of y-Glu-Gln also points toward a deficiency in the y-glutamyltransferase system, which could play a significant role in the pathophysiology of schizophrenia .
